ACCESSWIRE

General Atomics Aeronautical Systems, Inc.

Share
GA-ASI Mojave Lights Up the Yuma Desert in Live-Fire Demonstration

Minigun Integration Showcases the Firepower and Versatility of STOL UAS; Highlights Ability to Rapidly Integrate New Multi-Mission Capabilities

SAN DIEGO, CA / ACCESSWIRE / April 23, 2024 / General Atomics Aeronautical Systems, Inc. (GA-ASI) confirms that its Mojave Unmanned Aircraft System (UAS) destroyed static targets in live-fire tests on April 13, 2024, validating the system's battlefield relevance and recording another milestone for the demonstrator aircraft.

To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.

GA-ASI partnered with Dillon Aero to mount two of Dillon's DAP-6 Gun Pod Systems onto the Mojave aircraft. Mojave performed seven passes across two flights during the demonstration, expending around 10,000 rounds of ammunition as the UAS shredded a variety of targets.

"Seeing our Mojave perform this live-fire demo really emphasizes the versatility of the Mojave UAS and what it can do," said GA-ASI President David R. Alexander. "Mojave has the ability to act as a sensor, shooter, and sustainer while mitigating threat environments and vulnerabilities and safeguarding human lives."

Mojave and its short takeoff and landing (STOL) capability has built significant interest in the military and aerospace communities. Mojave is unique: a UAS with significant payload capacity that can perform in areas once considered unsuitable for UAS operations. Its ability to take off and land from unimproved landing sites at short distances as well as operate from aircraft carriers - as it did in November 2023 as part of a demonstration with the United Kingdom's Royal Navy - is capturing imaginations and changing expectations about how large unmanned systems can be used.

The live-fire demonstration took place at Yuma Proving Ground, Arizona, and was funded via GA-ASI's internal research and development budget.

The Mojave technical demonstrator shares common systems and components with GA-ASI's modernized Gray Eagle 25M, effectively providing an expeditionary Gray Eagle STOL capability. In addition to a wing kit option for Gray Eagle, GA-ASI is planning one for the larger MQ-9B aircraft, which includes SkyGuardian® and SeaGuardian® models.

The actual Mojave STOL UAS with multi-mission payloads will be on display in GA-ASI's booth (#792) at the Army Aviation Mission Solutions Summit in Denver, Colorado, April 24-26, 2024.

About GA-ASI

General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.

For more information, visit www.ga-asi.com.

Avenger, Lynx, Predator, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.

Contact Information

GA-ASI Media Relations
asi-mediarelations@ga-asi.com
+1 (858) 524-8101

SOURCE: General Atomics Aeronautical Systems, Inc.

To view this piece of content from stats.nwe.io, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESSWIRE

DK

Subscribe to releases from ACCESSWIRE

Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESSWIRE

Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release

During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h

Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release

WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release

VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release

TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on

Accurate Background Partnering with Konfir to Provide Fast, Secure Instant Employment Verification in the United Kingdom5.12.2024 09:15:00 CET | Press release

IRVINE, CA / ACCESSWIRE / December 5, 2024 / Accurate Background, headquartered in Irvine, CA, and the largest privately held and minority-owned global provider of compliant background checks, drug and health screening, and workforce monitoring solutions, has announced a new partnership with Konfir, an innovative company providing employment verification technology in the UK. This collaboration will provide Accurate's clients access to Konfir's real-time verification tools via Accurate technology. Accurate's integration of Konfir's instant employment verification API will allow candidates to aggregate real-time data from multiple data sources including Payroll, HMRC, and Open Banking, streamlining screening processes and reducing time-to-hire. In addition, Accurate will now offer enhanced fraud mitigation tools through Konfir's suite of insights helping employers identify potential hiring risks more effectively. Kevin Stone, Sales & Marketing Director at Accurate, commented: "At Accura

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye